Europa Trial
Home
Sitemap
General Public Heathcare Professionals Virtual Press Office

New Indication in CAD

EUROPA calendar
ACC 2006 - Posters
ESC 2005 - Symposium
ESC 2005 - Oral sessions
ESC 2005 - Posters
AHA 2004 - Oral Session
ESC 2004 - Hotline
ESC 2004 - Symposium
ACC 2004
ESC 2003


EUROPA study
EUROPA Results
ESC 2003 Hotline - video
Rationale for EUROPA
Rationale for Perindopril
Design & Organisation
EUROPA investigators
EUROPA collaborating centres
EUROPA Recruitment


EUROPA Slide Set
Rationale and Design
Results
Clinical Implications


EUROPA publications


PERSUADE
PERSUADE Publications
PERSUADE Results
PERSUADE Fact Sheet


PERTINENT
PERTINENT Results
PERTINENT Fact Sheet


Background : Coronary Artery Disease
Home : Healthcare professionals : PERTINENT Fact Sheet
PERTINENT Fact Sheet


Objective

To determine the mechanisms by which the ACE inhibitor perindopril significantly improved outcomes in patients with stable coronary artery disease (as observed in the EUROPA study).

Rationale

EUROPA showed that treatment with perindopril reduced the primary endpoint, i.e., combined risk of cardiovascular death, myocardial infarction and cardiac arrest, by 20 per cent (p=0.0003). Blood pressure lowering alone cannot be completely responsible for the observed benefits of perindopril, as a similar result was observed in people with stable coronary artery disease who had low or high blood pressure at entry into the study, or whose blood pressure did not fall during the study.

By acting on the angiotensin II / bradykinin balance, ACE inhibitors are thought to have an impact on endothelial dysfunction. Endothelial dysfunction can be considered as a biomarker of vascular disease as it predisposes the vascular wall to vasoconstriction, vascular inflammation, platelet activation, thrombosis, and atherosclerosis.

The PERTINENT study therefore set out to establish if the benefits achieved by perindopril observed in EUROPA were due to the drug’s effect on endothelial function and markers of inflammation and thrombosis.


Lead Author of Study

Professor Roberto Ferrari, Professor of Cardiology, University of Ferrara, Italy


Methodology

Several parameters were measured:

Human umbilical vein endothelial cells (HUVEC) function in terms of (1) endothelial cell nitric oxide synthase (ecNOS) expression and activity, of (2) rate of endothelial apoptosis
Blood levels of angiotensin II
Blood levels of bradykinin
Blood levels of TNF-α
Blood levels of von Willebrand factor


Study design

Human umbilical vein endothelial cells (HUVECs), a type of endothelial cell, were incubated with blood taken from either normal matched controls (n=45), or from EUROPA patients before and after 1 year of treatment with either perindopril (n=43) or placebo (n=44).


Results

Results showed in the treated patients group:

A significant increase in ecNOS activity
A significant reduction in endothelial apoptosis rate
A significant reduction in angiotensin II levels
A significant increase in bradykinin levels
A significant decrease in TNF-α
A significant reduction in von Willebrand factor

A significant correlation was observed between bradykinin and ecNOS activity. The levels of von Willebrand factor are predictive for cardiovascular outcomes.


Conclusion

These results indicate that coronary artery disease progression correlates with endothelial dysfunction and biological abnormalities. Perindopril in stable coronary artery disease modifies the biochemical parameters involved in inflammation and thrombosis, and improves endothelial dysfunction through mechanisms that are partially dependent on increased bradykinin.
Perindopril also reduces vWf levels that are predictive for outcomes. Taken together, these results confirm the vascular and anti-atherosclerotic effects of the ACE inhibitor perindopril and partly explain the results of EUROPA.

This website is intended for an international audience. Drug related information may refer to unlicensed products or uses which may not be approved in your own country and you should therefore consult your local prescribing information.
This site is published and updated by the EUROPA study investigators. Site last updated March 21st 2006
To report a suspected side-effect with a Servier drug, please click here.
Terms of use - ©2005 EUROPA All rights reserved